Insider Selling: Janux Therapeutics, Inc. (NASDAQ:JANX) Major Shareholder Sells $92,186.86 in Stock

Janux Therapeutics, Inc. (NASDAQ:JANX) major shareholder Ventures Xi L.P. Avalon sold 1,843 shares of Janux Therapeutics stock in a transaction that occurred on Thursday, October 17th. The shares were sold at an average price of $50.02, for a total value of $92,186.86. Following the completion of the transaction, the insider now owns 6,371 shares of the company’s stock, valued at approximately $318,677.42. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Large shareholders that own 10% or more of a company’s stock are required to disclose their sales and purchases with the SEC.

Ventures Xi L.P. Avalon also recently made the following trade(s):

• On Monday, September 30th, Ventures Xi L.P. Avalon sold 958 shares of Janux Therapeutics stock. The stock was sold at an average price of $46.24, for a total value of $44,297.92.
• On Friday, September 27th, Ventures Xi L.P. Avalon sold 49,231 shares of Janux Therapeutics stock. The stock was sold at an average price of $46.45, for a total value of $2,286,779.95.
• On Thursday, September 12th, Ventures Xi L.P. Avalon sold 158,031 shares of Janux Therapeutics stock. The shares were sold at an average price of $47.00, for a total transaction of $7,427,457.00.
• On Friday, September 6th, Ventures Xi L.P. Avalon sold 108,365 shares of Janux Therapeutics stock. The stock was sold at an average price of $42.00, for a total transaction of $4,551,330.00.
• On Monday, September 9th, Ventures Xi L.P. Avalon sold 2,182 shares of Janux Therapeutics stock. The stock was sold at an average price of $42.33, for a total transaction of $92,364.06.

Janux Therapeutics Trading Up 0.4 %

JANX stock opened at $50.03 on Monday. Janux Therapeutics, Inc. has a one year low of $5.65 and a one year high of $65.60. The firm has a market capitalization of $2.59 billion, a PE ratio of -41.01 and a beta of 3.54. The firm has a 50-day moving average of $45.81 and a two-hundred day moving average of $45.52.

Janux Therapeutics (NASDAQ:JANX) last posted its quarterly earnings data on Wednesday, August 7th. The company reported ($0.11) EPS for the quarter, topping analysts’ consensus estimates of ($0.31) by $0.20. Janux Therapeutics had a negative net margin of 291.17% and a negative return on equity of 8.78%. The firm had revenue of $8.90 million during the quarter, compared to analyst estimates of $0.77 million. The business’s quarterly revenue was up 709.1% compared to the same quarter last year. On average, equities research analysts anticipate that Janux Therapeutics, Inc. will post -1.18 earnings per share for the current year.

Institutional Trading of Janux Therapeutics

Several large investors have recently made changes to their positions in the stock. Capstone Investment Advisors LLC acquired a new stake in shares of Janux Therapeutics in the first quarter valued at about $1,969,000. Janus Henderson Group PLC boosted its stake in Janux Therapeutics by 1.8% during the 1st quarter. Janus Henderson Group PLC now owns 1,965,546 shares of the company’s stock valued at $73,961,000 after purchasing an additional 34,069 shares during the period. Price T Rowe Associates Inc. MD acquired a new stake in Janux Therapeutics in the 1st quarter valued at approximately $739,000. Virtu Financial LLC bought a new position in Janux Therapeutics in the 1st quarter worth approximately $609,000. Finally, Vanguard Group Inc. lifted its holdings in shares of Janux Therapeutics by 38.6% during the first quarter. Vanguard Group Inc. now owns 1,357,960 shares of the company’s stock worth $51,127,000 after buying an additional 378,477 shares during the last quarter. Institutional investors own 75.39% of the company’s stock.

Analyst Upgrades and Downgrades

JANX has been the topic of a number of recent analyst reports. Scotiabank cut their price target on Janux Therapeutics from $47.00 to $42.00 and set a “sector perform” rating on the stock in a report on Friday, August 9th. Stifel Nicolaus initiated coverage on Janux Therapeutics in a research report on Friday, September 6th. They set a “buy” rating and a $70.00 price target for the company. HC Wainwright reissued a “buy” rating and set a $63.00 price target on shares of Janux Therapeutics in a report on Monday, August 19th. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $100.00 price objective on shares of Janux Therapeutics in a report on Monday, September 16th. Finally, Wedbush reiterated an “outperform” rating and issued a $74.00 target price on shares of Janux Therapeutics in a research report on Thursday, August 8th. One analyst has rated the stock with a hold rating and eight have issued a buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $66.13.

Janux Therapeutics Company Profile

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.